Paradigm Biopharmaceuticals activates Hong Kong trial site for Phase III osteoarthritis study. The ASX-listed biotech company has begun screening participants for its global PARA_OA_012 trial testing injectable pentosan polysulfate sodium for knee osteoarthritis treatment. The company approaches a critical 50% patient recruitment milestone that will trigger interim analysis later this year. The randomized placebo-controlled trial will enroll 466 participants across Hong Kong and Moldova, with dosing over 112 days and weekly pain reduction as the primary endpoint. Paradigm strengthened its global recruitment network through partnerships with NBCD and Advanced Clinical to manage sites across multiple regions. The stock last traded at 26 cents as the company progresses toward completing Phase III enrollment.
Post from MarketNews_en
Log in to interact with content.